You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Raloxifene reduced vertebral fractures and breast cancer regardless of prior hormone therapy use in women

https://doi.org/10.1136/ebm.10.3.84

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Johnell O, Cauley JA, Kulkarni PM, et al. Raloxifene reduces risk of vertebral fractures and breast cancer in postmenopausal women regardless of prior hormone therapy. J Fam Pract 2004;53:789–96.
    OpenUrlPubMedWeb of Science

    
 
 Q In postmenopausal women with osteoporosis, does previous hormone therapy (HT) influence the effect of raloxifene on the risk of vertebral fractures and breast cancer?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Gynaecology ★★★★★★☆ Oncology ★★★★★★☆ Endocrine ★★★★★★☆

    METHODS

    Embedded ImageDesign:

    randomised placebo controlled trial (the Multiple Outcomes of Raloxifene Evaluation [MORE] trial).

    Embedded ImageAllocation:

    {concealed*}†.

    Embedded ImageBlinding:

    blinded {patients, healthcare providers, and outcome assessors}†.*

    Embedded ImageFollow up period:

    4 years.

    Embedded ImageSetting:

    {180 clinical centres in 25 countries}†.

    Embedded ImagePatients:

    7705 postmenopausal women ⩽80 years of age (mean age 67 y) with osteoporosis. 7682 women (99.7%) reported HT status; 2235 women (29.1%) had used HT previously. Exclusion criteria included other bone diseases and history of breast or endometrial cancer

    Embedded ImageIntervention:

    among women with …

    View Full Text

    Footnotes